As of 2025-04-29, the Intrinsic Value of Eupraxia Pharmaceuticals Inc (EPRX.TO) is -3.56 CAD. This EPRX.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 5.34 CAD, the upside of Eupraxia Pharmaceuticals Inc is -166.61%.
Based on its market price of 5.34 CAD and our intrinsic valuation, Eupraxia Pharmaceuticals Inc (EPRX.TO) is overvalued by 166.61%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.56 - -3.56 | -3.56 | -166.61% |
| P/E | 5.34 - 5.34 | 5.34 | -0.1% |
| DDM - Stable | (5.79) - (14.63) | (10.21) | -291.3% |
| DDM - Multi | (1.44) - (2.85) | (1.92) | -135.9% |
| Market Cap (mil) | 191.44 |
| Beta | 0.77 |
| Outstanding shares (mil) | 35.85 |
| Enterprise Value (mil) | 158.34 |
| Market risk premium | 5.10% |
| Cost of Equity | 10.49% |
| Cost of Debt | 5.00% |
| WACC | 7.09% |